Quick Answer
IOVANCE BIOTHERAPEUTICS, INC. reported Net Income Loss of -$390.98 million for the year ending 2025.
- IOVANCE BIOTHERAPEUTICS, INC. showed a decrease of -5.1% in Net Income Loss from 2024 to 2025.
- This data is from IOVANCE BIOTHERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: -$2.11 million | Q3 2014: -$3.01 million | Q4 2014: -$4.65 million | Q1 2015: -$5.30 million | Q2 2015: -$6.37 million | Q3 2015: -$7.64 million | Q4 2015: -$8.36 million | Q1 2016: -$6.88 million | Q2 2016: -$11.56 million | Q3 2016: -$68.21 million | Q4 2016: -$15.69 million | Q1 2017: -$20.68 million | Q2 2017: -$23.38 million | Q3 2017: -$22.15 million | Q4 2017: -$25.85 million | Q1 2018: -$26.52 million | Q2 2018: -$30.66 million | Q3 2018: -$33.83 million | Q4 2018: -$32.58 million | Q1 2019: -$36.95 million | Q2 2019: -$47.55 million | Q3 2019: -$49.49 million | Q4 2019: -$63.57 million | Q1 2020: -$69.60 million | Q2 2020: -$63.02 million | Q3 2020: -$58.57 million | Q4 2020: -$68.40 million | Q1 2021: -$75.45 million | Q2 2021: -$81.35 million | Q3 2021: -$86.12 million | Q1 2022: -$91.61 million | Q2 2022: -$99.35 million | Q3 2022: -$99.62 million | Q1 2023: -$107.37 million | Q2 2023: -$106.53 million | Q3 2023: -$113.76 million | Q1 2024: -$112.98 million | Q2 2024: -$97.10 million | Q3 2024: -$83.54 million | Q1 2025: -$116.16 million | Q2 2025: -$111.66 million | Q3 2025: -$91.25 million.
- Over the full 18 years of available data (2008 to 2025), IOVANCE BIOTHERAPEUTICS, INC.'s Net Income Loss has declined by 665,779.8%.
- Historical annual values: Fiscal year 2025: -$390.98 million | Fiscal year 2024: -$372.18 million | Fiscal year 2023: -$444.04 million | Fiscal year 2022: -$395.89 million | Fiscal year 2021: -$342.25 million | Fiscal year 2020: -$259.58 million | Fiscal year 2019: -$197.56 million | Fiscal year 2018: -$123.58 million | Fiscal year 2017: -$92.06 million | Fiscal year 2016: -$52.89 million | Fiscal year 2015: -$27.66 million | Fiscal year 2014: -$12.04 million | Fiscal year 2013: -$25.38 million | Fiscal year 2012: -$3.31 million | Fiscal year 2011: -$25.69 million | Fiscal year 2010: -$1.61 million | Fiscal year 2009: -$15.8 thousand | Fiscal year 2008: -$58.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: